Leerink analyst Joseph Schwartz notes BioMarin (BMRN) believes INZ-701 could be a $400M-$600M opportunity at peak, making it ...

Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the launch ...

Detailed price information for Aura Biosciences Inc (AURA-Q) from The Globe and Mail including charting and trades.

With its purchase of Boston Pharmaceuticals' drug, GSK extends a streak of dealmaking it's undertaken to build a liver ...

Halozyme Therapeutics (HALO) stock remains under pressure as Morgan Stanley downgrades the company on Medicare price negotiation concerns. Read more here.

Fintel reports that on May 14, 2025, Leerink Partners downgraded their outlook for iTeos Therapeutics (NasdaqGM:ITOS) from ...

Fintel reports that on May 13, 2025, Leerink Partners downgraded their outlook for Halozyme Therapeutics (NasdaqGS:HALO) from ...